ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 286

Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis

Elizabeth Coulson1, Wan-Fai Ng2, Philip N. Platt3 and H. E. Foster4, 1Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, 3Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 4Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Cardiovascular disease and juvenile idiopathic arthritis (JIA)

Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Increased cardiovascular mortality and morbidity have been observed in adults with Rheumatoid Arthritis. The long-term risk of cardiovascular disease for individuals with Juvenile Idiopathic Arthritis (JIA) remains uncertain. This study aims to determine whether adults with JIA have an increased risk of cardiovascular disease compared to the general population.

Methods:

51 patients with JIA (mean age 35.6 years, SD 13.23) were compared to 26 controls (mean age 37.3 years, SD 13.14). Data regarding traditional cardiovascular risk factors were collected including fasting blood glucose and lipid profile, blood pressure, BMI and history of hypertension, hypercholesterolaemia, diabetes mellitus, smoking history and family history of cardiovascular disease. Disease sub-type (ILAR criteria) and duration were recorded. In the patient group the sub-types were as follows: systemic 3/51 (5.9%), enthesitis-related arthritis (ERA) 5/51 (9.8%), extended oligoarticular 12 /51 (23.5%), polyarticular 27/51 (52.9%), juvenile psoriatic (JPSA) 4/51 (7.8%). Median disease duration was 24 years (3-57). Many (23/51 (45%)) patients were taking biological therapy, 13 as monotherapy and 10 in combination with a DMARD; a further 17/51 (33%) patients were taking one or more DMARDs. Common carotid artery intima-media thickness (CCA IMT) was examined by B-mode ultrasound (Toshiba AplioXU and 12 MHz transducer) as a surrogate marker of cardiovascular disease. Images were analysed blinded using the M’athñ software package (Intelligence in Medical Technologies). Continuous, parametric variables were analysed using the independent samples T-test, non-parametric using the Mann Whitney U test and categorical data using the chi-squared test.

Results:

The Table shows that a significantly higher proportion of patients had a pre-existing diagnosis of hypertension compared to controls (p=0.029) but no significant differences in other pre-existing traditional cardiovascular risk factors. The patient group had a significantly higher CRP (p=0.006). No significant differences were found in ESR, fasting glucose or lipid levels, BMI or systolic or diastolic blood pressures recorded in clinic.  CCA IMT showed good correlation with age (Pearson’s coefficient 0.76, p=0.000). The patient group had a significantly higher mean CCA IMT (0.54 vs. 0.49, p=0.037) compared to controls. Subgroup analysis revealed a significantly higher mean CCA IMT in those with polyarticular disease (0.56 vs. 0.48, p=0.01), but not for other subtypes. CCA IMT was not significantly higher in patients taking biologics (0.51 vs. 0.49 p=0.396) but was for those taking DMARDs (0.58 vs. 0.48, p=0.029) compared to controls.

Conclusion:

Adults with JIA were found to have an increased cardiovascular risk measured using carotid IMT compared to age- and sex-matched controls. This may in part be explained by an increased prevalence of hypertension.

Patient n=51

Control n=26

P value

Hypertension n(%)

12 (23.5)

1 (3.9)

0.029

Hypercholesterolaemia n(%)

4 (7.8)

1 (3.9)

0.501

Diabetes mellitus n(%)

2 (3.9)

1 (3.9)

0.987

Family history of cardiovascular disease n(%)

6 (11.8)

3 (11.5)

0.771

Smoking history n(%)

Ever

12 (23.5)

Ever

3 (11.5)

0.305

Never

39 (76.5)

Never

23 (88.5)

Pack Years (mean)

10.4

8.5

CRP (mg/l) mean (SD)

9.0 (9.02)

5.6 (1.97)

0.006

ESR (mm/hr) mean (SD)

12.6 (12.75)

6.4 (7.70)

0.106

BMI (kg/m2) mean (SD)

25.0 (6.5)

24.9 (4.3)

0.483

Systolic BP (mmHg) mean (SD)

122 (15.4)

120 (14.0)

0.684

Diastolic BP (mmHg) mean (SD)

79 (10.1))

78 (8.6)

0.859

Glucose (mmol/l) mean (SD)

4.9 (1.87)

4.9 (0.34)

0.496

Cholesterol (mmol/l) mean (SD)

4.6 (0.97)

4.8 (1.00)

0.417

Triglycerides (mmol/l) mean (SD)

1.04 (0.51)

1.01 (0.61)

0.374

HDL (mmol/l) mean (SD)

1.5 (0.49)

1.7 (0.45)

0.109

LDL (mmol/l) mean (SD)

2.5 (1.04)

2.6 (1.06)

0.954

CCA IMT (mm) mean (SD)

0.54 (0.10)

0.49 (0.08)

0.037

Polyarticular n=27

0.56 (0.11)

0.48 (0.08)

0.010

JPSA n=4

0.48 (0.07)

0.46 (0.02)

0.289

Systemic n=3

0.68 (0.05)

0.51 (0.07)

0.050

Extended oligoarticular n=12

0.51 (0.65)

0.46 (0.42)

0.054

ERA n=5

0.46 (0.06)

0.47 (0.09)

0.806


Disclosure:

E. Coulson,
None;

W. F. Ng,
None;

P. N. Platt,
None;

H. E. Foster,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-in-adults-with-juvenile-idiopathic-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology